Tesamorelin 30mg Growth Hormone-Releasing Factor Analog

Tesamorelin is a synthetic growth hormone-releasing factor (GRF) analog that stimulates the pituitary gland to release growth hormone and subsequently increases IGF-1 levels. It has been clinically studied for its effects on excess abdominal fat in adults with HIV-associated lipodystrophy.

Research areas include: growth-hormone signalling, IGF-1 pathways, body-composition research, abdominal adipose tissue, metabolic health and effects associated with HIV-related lipodystrophy. Tesamorelin research has also examined its effects on adipose tissue and related metabolic markers.

Important: Tesamorelin is an FDA-approved prescription medicine for a specific indication, but the 30mg self-mix vial shown here is not equivalent to an FDA-approved tesamorelin formulation. Approved Egrifta formulations are supplied in different strengths and presentations. This specific product should not be represented as an approved pharmaceutical product.

The Certificate of Analysis for lot GX-2026 confirms an HPLC purity of 99%+ and identity confirmed by mass spectrometry.

The Safety Data Sheet describes handling, storage and disposal information for this research compound. Always follow standard laboratory safety practice.